OSE Immunotherapeutics in trouble after disappointing clinical trial

French biotech OSE Immunotherapeutics is going through a critical period after disappointing clinical trial results.

Published 7sem1 sourceImportantupdated 5j

≈ 17sSpeed

The fact

Investors express concern about the group's therapeutic and commercial prospects.

Visibility on coming months appears limited for the stock.

Click the link to read an article on the topic:

Explore this topic

Auto-synthesis from 1 media source · identified on June 2, 2026